Semaglutide is not indicated for type 1 diabetes or diabetic ketoacidosis
Patients with baseline hypomagnesemia, a history of bowel obstruction, or severe IBS should consult their provider before significant fiber escalation
Pregnant or nursing women should consult a healthcare professional before using this supplement
Supports detoxification, brain health and cellular functions
Fewer Side Effects Some people stop GLP-1s early due to nausea, reflux, constipation, or fatigue
Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
